| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IMUX Stock Overview
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.77 |
| 52 Week High | US$28.21 |
| 52 Week Low | US$6.96 |
| Beta | 1.94 |
| 1 Month Change | -1.31% |
| 3 Month Change | 12.30% |
| 1 Year Change | -43.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.49% |
Recent News & Updates
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Shareholder Returns
| IMUX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.6% | -7.4% | -6.1% |
| 1Y | -43.8% | -22.0% | 4.2% |
Return vs Industry: IMUX underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: IMUX underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| IMUX volatility | |
|---|---|
| IMUX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: IMUX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IMUX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 52 | Daniel Vitt | https://www.immunic-therapeutics.com |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR
Immunic Fundamentals Summary
| IMUX fundamental statistics | |
|---|---|
| Market Cap | US$256.46m |
| Earnings (TTM) | -US$82.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs IMUX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMUX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Expenses | US$82.92m |
| Earnings | -US$82.92m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMUX perform over the long term?
See historical performance and comparisonValuation
Is Immunic undervalued compared to its fair value and its price relative to the market?
1.76x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMUX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IMUX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMUX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMUX is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (1.9x).
Future Growth
How is Immunic forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
28.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMUX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMUX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMUX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMUX is forecast to have no revenue next year.
High Growth Revenue: IMUX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMUX's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Immunic performed over the past 5 years?
-49.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMUX is currently unprofitable.
Growing Profit Margin: IMUX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMUX is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.
Accelerating Growth: Unable to compare IMUX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMUX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: IMUX has a negative Return on Equity (-57%), as it is currently unprofitable.
Financial Health
How is Immunic's financial position?
Financial Position Analysis
Short Term Liabilities: IMUX's short term assets ($122.5M) exceed its short term liabilities ($10.6M).
Long Term Liabilities: IMUX's short term assets ($122.5M) exceed its long term liabilities ($701.0K).
Debt to Equity History and Analysis
Debt Level: IMUX is debt free.
Reducing Debt: IMUX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMUX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMUX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 47.2% each year.
Dividend
What is Immunic current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMUX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMUX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMUX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMUX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMUX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Daniel Vitt (53 yo)
2.75yrs
Tenure
US$1,318,054
Compensation
Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since April 2019 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG in No...
CEO Compensation Analysis
Compensation vs Market: Daniel's total compensation ($USD1.32M) is about average for companies of similar size in the US market ($USD1.14M).
Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: IMUX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Experienced Board: IMUX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.7%.
Top Shareholders
Company Information
Immunic, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Immunic, Inc.
- Ticker: IMUX
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$256.457m
- Shares outstanding: 26.25m
- Website: https://www.immunic-therapeutics.com
Number of Employees
Location
- Immunic, Inc.
- 1200 Avenue of the Americas
- Suite 200
- New York
- New York
- 10036
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 23:13 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.